Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl) methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 14, 2012, Pages 4590-4597

  Mun, Jiyoung ^a   Jabbar, Adnan Abdul ^b   Devi, Narra Sarojini ^b   Liu, Yuan ^a,c   Van Meir, Erwin G ^a,b   Goodman, Mark M ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

3,4 Dimethoxy N (2,2 dimethyl 2H chromen 6 yl)methyl N phenylbenzenesulfonamide; Anti cancer drugs; Brain cancer; Hypoxia inducible factor 1; Small molecule HIF 1 transcription factor inhibitors; Structure activity relationships; Tumor hypoxia

Indexed keywords

1 (2,2 DIMETHYL 2H CHROMENE 6 YL) N (4 FLUOROPHENYL)METHANIMINE; 1 (2,2 DIMETHYL 2H CHROMENE 6 YL) N (PROPAN 2 YL)METHANIMINE; 1 (2,2 DIMETHYL 2H CHROMENE 6 YL) N PHENYLMETHANIMINE; 2,2 DIMETHYL 2H CHROMENE 6 CARBALDEHYDE; 2,2 DIMETHYL 2H CHROMENE DERIVATIVE; 2,2 DIMETHYLCHROMENE DERIVATIVE; 2,5 DICHLORO N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N (PROPAN 2 YL)BENZENESULFONAMIDE; 2,5 DICHLORO N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N PHENYLBENZENESULFONAMIDE; 3,4 DIMETHOXY N [(2,2 DIMETHYL 2H CHROMEN 6 YL)METHYL] N PHENYLBENZENESULFONAMIDE DERIVATIVE; 3,4 DIMETHOXY N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N (FLUOROPHENYL)BENZENESULFONAMIDE; 3,4 DIMETHOXY N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N (PROPAN 2 YL)BENZENESULFONAMIDE; 3,4 DIMETHOXY N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N PHENYLBENZENESULFONAMIDE; 4 [(2 METHYLBUT 3 YN 2 YL)OXY]BENZALDEHYDE; ANTINEOPLASTIC AGENT; ARYLSULFONAMIDE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] 4 FLUORO N (FLUOROPHENYL)BENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] 4 FLUORO N (PROPAN 2 YL)BENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] 4 FLUOROANILINE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] 4 NITRO N (PROPAN 2 YL)BENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] 4 NITRO N PHENYLBENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N (FLUOROPHENYL) 4 NITROBENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N (FLUOROPHENYL)BENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N (PROPAN 2 YL)BENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL] N PHENYLBENZENESULFONAMIDE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL]ANILINE; N [(2,2 DIMETHYL 2H CHROMENE 6 YL)METHYL]PROPAN 2 AMINE; NEW DRUG; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL LINE, TUMOR; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 84863187240     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.04.064     Document Type: Article

References (30)

1. D.E. Post, N.S. Devi, Z. Li, D.J. Brat, B. Kaur, A. Nicholson, J.J. Olson, Z. Zhang, and E.G. Van Meir Clin. Cancer Res. 10 2004 8603
2. H.-S. Kim, G.-Y. Peng, J.M. Hicks, H.L. Weiss, E.G. Van Meir, M.K. Brenner, and P. Yotnda Mol. Ther. 16 2008 599
3. D.E. Post, E.M. Sandberg, S.N. Devi, D.J. Brat, Z. Xu, M. Tighiouart, and E.G. Van Meir Cancer Res. 67 2007 6872
4. A.L. Harris Nat. Rev. Cancer. 2 2002 38
5. B. Kaur, F.W. Khwaja, E.A. Severson, S.L. Matheny, D.J. Brat, and E.G. Van Meir Neuro-Oncology 7 2005 134
6. R.L. Jensen, B.T. Ragel, K. Whang, and D. Gillespie J. Neuro-Oncol. 78 2006 233
7. A.L. Kung, S. Wang, J.M. Klco, W.G. Kaelin Jr., and D.M. Livingston Nat. Med. 6 2006 1335
8. A. Rapisarda, M. Hollingshead, B. Uranchimeg, C.A. Bonomi, S.D. Borgel, J.P. Carter, B. Gehrs, M. Raffeld, R.J. Kinders, R. Parchment, M.R. Anver, R.H. Shoemaker, and G. Melillo Mol. Cancer Ther. 2009 1867 8
9. D.L. Gillespie, K. Whang, B.T. Ragel, J.R. Flynn, D.A. Kelly, and R.L. Jensen Cancer Ther. 13 2007 2441
10. L. Li, X. Lin, A.R. Shoemaker, D.H. Albert, S.W. Fesik, and Y. Shen Cancer Ther. 12 2006 4747
11. G.L. Semenza Oncogene 29 2010 625
12. V.E. Belozerov, and E.G. Van Meir Anti-Cancer Drugs 16 2005 901
13. V. Belozerov, and E.G. Van Meir Curr. Opin. Invest. Drugs 7 2006 1067
14. T. Narita, S. Yin, C.F. Gelin, C.S. Moreno, M. Yepes, K.C. Nicolaou, and E.G. Van Meir Clin. Cancer Res. 15 2009 6128
15. C. Tan, R.G. de Noronha, A.J. Roecker, B. Pyrzynska, F. Khwaja, Z. Zhang, H. Zhang, Q. Teng, A.C. Nicholson, P. Giannakakou, W. Zhou, J.J. Olson, M.M. Pereira, K.C. Nicolaou, and E.G. Van Meir Cancer Res. 65 2005 605
16. S. Welsh, R. Williams, L. Kirkpatrick, G. Pain-Murrieta, and G. Powis Mol. Cancer Ther. 3 2004 233
17. K.C. Nicolaou, J.A. Pfefferkorn, A.J. Roecker, G.-Q. Cao, S. Barluenga, and H.J. Mitchell J. Am. Chem. Soc. 122 2000 9939
18. K.C. Nicolaou, J.A. Pfefferkorn, H.J. Mitchell, A.J. Roecker, S. Barluenga, G.-Q. Cao, R.L. Affleck, and J.E. Lillig J. Am. Chem. Soc. 122 2000 9954
19. C. Tan, R.G. de Noronha, N.S. Devi, A.A. Jabbar, S. Kaluz, Y. Liu, S. Reid-Mooring, K.C. Nicolaou, B. Wang, and E.G. Van Meir Bioorg. Med. Chem. Lett. 21 2011 5528
20. Van Meir, E. G.; Nicolaou, K. C. U.S. Patent 033 286, 2005.
21. S.R. Mooring, H. Jin, N.S. Devi, A.A. Jabbar, S. Kaluz, Y. Liu, E.G. Van Meir, and B. Wang J. Med. Chem. 54 2011 8471
22. Van Meir, E. G.; Chalet, T.; Roecker, A.; Nicolaou, K. C. US patent 009,548. Mar 29, 2004.
23. L.R. Smith, N. Mahoney, and R.J. Molyneux J. Nat. Prod. 66 2003 169
24. S. Prado, Y.L. Janin, B. Saint-Joanis, P. Brodin, S. Michel, M. Koch, S.T. Cole, F. Tillequin, and P.-E. Bost Bioorg. Med. Chem. 15 2007 2177
25. A.W. Grubbs, G.D. Artman III, and R.M. Williams Tetrahedron Lett. 46 2005 9013
26. N. Ishii, D. Maier, A. Merlo, M. Tada, Y. Sawamura, A.-C. Diserens, and E.G. Van Meir Brain Pathol. 9 1999 469
27. D.E. Post, and E.G. Van Meir Gene Ther. 2001 1801 8
28. G.L. Semenza Nat. Rev. Cancer 3 2003 721
29. C.E. Stebbins, W.G. Kaelin Jr., and N.P. Pavletich Science 284 1999 455
30. T. Kamura, D.M. Koepp, M.N. Conrad, D. Skowyra, R.J. Moreland, O. Iliopoulos, W.S. Lane, W.G. Kaelin Jr., S.J. Elledge, and R.C. Conaway Science 284 1999 657